Skip to content
DataLookout
Menu

NCT05472818

SV2A Density Cannabis Use Disorder

StatusCompleted
PhaseEarly Phase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 5 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 34 words Show 6 more changesShow less
    • Trial completed
    • Final enrollment: 42 participants (planned 51)
    • Primary completion date changed from estimate of May 30, 2027 to Apr 28, 2026
    • Study completion date changed from estimate of May 2032 to May 14, 2026
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised
  2. Minor Enrollment target: 42 to 51v8
  3. Minor Primary completion date: May 2027 to May 30, 2027
    • Start date: May 1, 2022 to Apr 12, 2022
    v6
  4. Minor Start date changed from estimate of Jul 2022 to May 1, 2022v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Hippocampal SV2A synaptic density
Timeframe: All participants will receive at least two [11C]APP311 (UCB-J) PET scans approx. 4 weeks days apart.

Secondary (2)

Hippocampal binding and Hippocampal Verbal Memory Task
Hippocampal binding and Groton Maze Learning in CUDs

Arms and interventions

CUD GroupActive comparator

Participants will be scanned using anatomical magnetic resonance imaging (MRI) and PET. All participants will receive two PET scans, 4 weeks apart. CUD participants will be asked to abstain from cannabis for the 4 week period.

Healthy ControlsActive comparator

Participants will be scanned using anatomical magnetic resonance imaging (MRI) and PET. All participants will receive two PET scans, 4 weeks apart.

Drugs: [11C]APP311

Sites

1 site in 1 country

  • Yale University School of MedicineNew Haven, Connecticut, United States